EUVIMEDEUVIMED entdecken
Crossref

Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma

Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Moe Nomura-Yogo, Yuki Oda, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Tadao Ishida

International Journal of Hematology · 2024

DOI: 10.1007/s12185-024-03770-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Taku Kikuchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Japanese Red Cross Medical Center, 4-chōme-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan. taku_k_1123@mac.com. Hauptthemen laut MEDLINE: Multiple Myeloma, Cytomegalovirus Infections, Antibodies, Monoclonal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of daratumumab has improved treatment outcomes for multiple myeloma (MM). However, infectious complications are a concern in patients receiving daratumumab. Although some reports have explored the association between daratumumab and cytomegalovirus (CMV) infection, most of these have focused on relapsed or refractory cases, and few describe patients with newly diagnosed MM (NDMM). In this study, we retrospectively analyzed CMV infections in 53 patients with NDMM who received daratumumab as induction therapy. CMV infection was defined as CMV antigenemia positivity. The median age at treatment initiation was 71 years (range, 50-82 years), and 50.9% of the patients were female. The median duration of daratumumab administration was 10.0 months (range, 0.3-63.8 months). Nine patients developed CMV infection, and the cumulative incidence rate at six months was 18.1% (95% confidence interval: 8.9-30.1%). One patient experienced CMV retinitis and required antiviral therapy, while the remaining eight patients did not require treatment and could be managed through observation. Few cases of CMV infection during daratumumab treatment for NDMM required treatment. However, the incidence of CMV infection was not negligible, suggesting that regular monitoring for CMV is worth considering to ensure more appropriate management during daratumumab treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaCytomegalovirus InfectionsAntibodies, MonoclonalHumansAgedMiddle AgedFemaleMaleAged, 80 and overRetrospective StudiesIncidenceCytomegalovirus

Stichwörter der Autor:innen

Cytomegalovirus infectionDaratumumabNewly diagnosed multiple myeloma

Substanzen

daratumumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Hematology, Japanese Red Cross Medical Center, 4-chōme-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan. taku_k_1123@mac.com.
  • Department of Hematology, Japanese Red Cross Medical Center, 4-chōme-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan.

Zitieren

APA

Kikuchi, T., Tsukada, N., Kunisada, K., Nomura-Yogo, M., Oda, Y., Sato, K., Takei, T., Ogura, M., Abe, Y., Suzuki, K., & Ishida, T. (2024). Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03770-8

Vancouver

Kikuchi T, Tsukada N, Kunisada K, Nomura-Yogo M, Oda Y, Sato K, et al. Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03770-8

BibTeX
@article{Kikuchi2024,
  author = {Kikuchi, Taku and Tsukada, Nobuhiro and Kunisada, Kodai and Nomura-Yogo, Moe and Oda, Yuki and Sato, Kota and Takei, Tomomi and Ogura, Mizuki and Abe, Yu and Suzuki, Kenshi and Ishida, Tadao},
  title = {Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma},
  journal = {International Journal of Hematology},
  year = {2024},
  doi = {10.1007/s12185-024-03770-8}
}
Kostenlos starten →